IP Library › Granted Patent US 11,767,351
Granted Patent B2
US 11,767,351 · App. 17/394,313 · Granted Sep 26, 2023

Recombinant lectin and uses thereof

Inventors: Markus Kalkum (Azusa, CA); Yoko Fujita-Yamaguchi (Pasadena, CA); Karine Bagramyan (North Hollywood, CA); Teresa B. Hong (El Monte, CA); Sarah Shuck (Orange, CA)
Assignee: CITY OF HOPE
C07K14/36A61K51/08G01N33/57419G01N33/57438G01N33/57492G01N33/582C07K2319/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,767,351
App. No.
17/394,313
Granted
Sep 26, 2023
Kind
B2
Abstract

Disclosed herein are a recombinant Streptomyces S27S5 hemagglutinin (SHA), and homologues thereof, and a fusion protein of a fluorescent protein (such as GFP and mCherry1) and SHA or a homologue thereof, which specifically bind to carbohydrates, including oligomeric sugars that terminate in L-rhamnose or D-galactose. The SHA, SHA homologues, and fusion proteins can be used to detect a variety of microorganisms or cancer or tumor antigens.

Claims (9)

1. A method of detecting a cancer or tumor in a subject, comprising:

contacting a sample obtained from the subject with a fusion protein comprising a fluorescent protein and a Streptomyces hemagglutinin (SHA) protein or a homologue of the SHA protein, wherein the SHA protein has an amino acid sequence represented by SEQ ID NO: 25, the homologue of the SHA protein has an amino acid sequence at least 90%, at least 95%, at least 98%, or at least 99% identical to that of SEQ ID NO: 25, wherein the homologue of the SHA protein comprises SEQ ID NO: 17, SEQ ID NO: 19, and SEQ ID NO: 21; and wherein the fusion protein specifically binds to L-rhamnose or D-galactose; and

detecting the fluorescence level in the sample, wherein the presence of fluorescence indicating the presence of the cancer or tumor,

wherein the cancer or tumor cell expresses an antigen comprising a carbohydrate capable of specifically binding to the SHA protein, the homologue of the SHA protein, or an SHA protein fragment or a homologue of the SHA protein fragment.

2. The method of claim 1 , wherein the sample includes a biopsy sample, a tissue sample, a bronchoalveolar lavage sample, a blood sample, and a urine sample.

3. The method of claim 1 , wherein the cancer is colon cancer, pancreatic ductal carcinoma, or pancreatic cancer.

4. The method of claim 1 , wherein the antigen is a surface antigen comprising a carbohydrate containing D-galactose.

5. The method of claim 1 , wherein the fusion protein specifically binds to a carbohydrate that contains or terminates in a monosaccharide or an oligosaccharide selected from the group consisting of β-Gal-; α-Rha-; Gal-α-1,3-Gal-β-1,3-GlcNAc-β-; Gal-α-1,3-Gal-β-1,4-Glc-β-; Gal-α-1,4-Gal-β-1,3-GlcNAc-β-; Gal-α-1,3-(Fuc-α-1,2)-Gal-β-; Gal-α-1,3-(Fuc-α-1,2)-Gal-β-1,4-Glc-β-; Gal-α-1,3-Gal-β-, Gal-α-1,4-Gal-β-1,4-Glc-β-; GalNAc-β-1,3-Gal-β-1,4-Glc-β-; and Gal-α-1,4-Gal-β-1,4-GlcNAc-β-.

6. The method of claim 1 , wherein the fluorescent protein includes GFP and mCherry1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2021
From: KALKUM, MARKUS; FUJITA-YAMAGUCHI, YOKO; BAGRAMYAN, KARINE; HONG, TERESA B.; SHUCK, SARAH
To: CITY OF HOPE
Reel/Frame 057771/0214 →
Continuity (4)
Division 16165725 · Oct 19, 2018
Provisional Application 62574626 · Oct 19, 2017
Provisional Application 62574636 · Oct 19, 2017
Related Publication 20210395315A1 · Dec 23, 2021